Form 4: Bristol-Myers Squibb Director Acquires Over 1,000 Deferred Share Units

Theodore R. Samuels II, a Director at Bristol-Myers Squibb Co., acquired 1,080.147 Deferred Share Units as part of his compensation plan, increasing his beneficial ownership to 59,477.227 units.

Summary

• Theodore R. Samuels II, a Director of Bristol-Myers Squibb Co. (BMY), acquired 1,080.147 Deferred Share Units.
• The transaction occurred on June 30, 2025.
• These units were acquired at a price of $0, indicating they are likely part of a compensation plan.
• Each Deferred Share Unit is convertible into one share of common stock upon settlement.
• Settlement occurs when Mr. Samuels ceases to be a director or at a previously specified future date.
• The acquisition increases Mr. Samuels' total beneficial ownership of Deferred Share Units to 59,477.227.
• This total includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The acquisition of deferred share units by a director, even as compensation, generally indicates continued alignment of interests with the company's long-term performance and is a positive signal for investor confidence, though it's a routine compensation event rather than a direct investment.

Positives

• A director, Theodore R. Samuels II, increased his beneficial ownership in Bristol-Myers Squibb Co. by acquiring 1,080.147 Deferred Share Units.
• The acquisition of units, even if compensation, aligns the director's interests with shareholders.

Future Outlook

The Deferred Share Units acquired by the director will convert into common stock upon his cessation as a director or at a future date previously specified by him, indicating a long-term alignment with the company's performance.

Industry Context

This transaction is a routine insider filing for a major pharmaceutical company, Bristol-Myers Squibb, reflecting standard director compensation practices within the industry where equity-based awards are common to align executive and director interests with shareholder value.

Comparison to Industry Standards

• The use of Deferred Share Units (DSUs) as a component of non-employee director compensation is a common practice across large-cap pharmaceutical and biotechnology companies, such as Pfizer, Merck, and Johnson & Johnson, aiming to align director incentives with long-term shareholder value.
• The acquisition of DSUs at a $0 price is typical for equity compensation awards, reflecting a grant rather than a purchase, consistent with compensation structures seen at peer companies.
• The mechanism for settlement (upon cessation of directorship or a specified future date) is a standard feature of such plans, encouraging long-term commitment and deferral of income.

Related Party Transactions

• The acquisition of Deferred Share Units by a director is a related party transaction, as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The transaction aligns the director's long-term interests with shareholders, as the value of the deferred units is tied to the company's stock performance.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The Deferred Share Units will be converted into common stock upon the reporting person ceasing to be a director or at a future date previously specified by the reporting person.

Key Dates

Recommendation

Keywords

Bristol-Myers Squibb, BMY, SEC Form 4, Insider Transaction, Deferred Share Units, Director Compensation, Equity Ownership, Theodore R. Samuels II, Pharmaceuticals, Biotechnology